RANI THERAPEUTICS HOLDINGS-A (RANI)
US7530181004 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 980K | 460K -53.06% | 2.72M 491.30% | 94.717K -100.00% | 8.867M | 36.262M 308.95% | 89.355M 146.41% | 204.36M 128.71% | 443.32M 116.93% | 433.37M -2.24% | ||||
| EBITDA YoY % growth | -26.51M | -15.95M 39.83% | -51.1M -220.38% | -62.401M -23.09% | -72.393M -3.78% | -51.933M 20.44% | -55.892M -7.62% | -60.186M -7.68% | -63.195M -5.00% | -36.002M 43.03% | -2.019M 94.39% | 109.51M 5,525.10% | 310.6M 183.63% | |
| EBIT YoY % growth | -27.07M | -16.54M 38.90% | -51.6M -211.97% | -64.541M -22.97% | -71.15M -4.17% | -51.867M 21.53% | -56.771M -9.46% | -53.257M 6.19% | -44.934M 15.63% | -21.807M 51.47% | 44.397M 303.59% | 205.91M 363.79% | 252.58M 22.67% | |
| Operating Margin | -2,762.24% | -3,595.65% | -1,897.06% | -68,140.35% | N/A | N/A | N/A | -600.62% | -123.91% | -24.40% | 21.72% | 46.45% | 58.28% | |
| EPS YoY % growth | N/A | N/A | N/A | -1.30 26.33% | -1.39 -3.91% | -1.02 23.50% | -0.99 2.76% | -0.72 27.58% | -0.63 12.46% | -0.41 34.96% | -0.17 58.75% | 0.56 433.33% | 1.75 211.82% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.24 9.33% | -0.21 26.14% | -0.21 17.62% | -0.21 10.75% | -0.22 8.33% | -0.25 -18.10% | -0.27 -25.71% | -0.28 -29.05% |
| Revenue Q2Q % growth | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | -12.809M -1.56% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.65M 5.84% | -13.541M 3.52% | -14.153M -13.00% | -14.816M -25.57% | -15.3M -20.95% | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.24 33.33% | -0.26 | 0.02 | 8.92% |
| Q2 2024 Q2Q % growth | -0.26 29.73% | -0.32 | 0.06 | 19.26% |
| Q1 2024 Q2Q % growth | -0.29 12.12% | -0.21 | -0.08 | -39.83% |
| Q4 2023 Q2Q % growth | -0.27 22.86% | -0.32 | 0.05 | 15.05% |
| Q3 2023 Q2Q % growth | -0.36 -9.09% | -0.37 | 0.01 | 3.48% |
| Q2 2023 Q2Q % growth | -0.37 -19.35% | -0.41 | 0.04 | 10.28% |
| Q1 2023 Q2Q % growth | -0.33 -13.79% | -0.42 | 0.09 | 21.76% |
| Q4 2022 Q2Q % growth | -0.35 -29.63% | -0.35 | 0.00 | 1.40% |
| Q3 2022 Q2Q % growth | -0.33 -175.00% | -0.48 | 0.15 | 30.87% |
| Q2 2022 Q2Q % growth | -0.31 -158.33% | -0.59 | 0.28 | 47.37% |
| Q1 2022 Q2Q % growth | -0.29 | -0.67 | 0.38 | 56.92% |
| Q4 2021 Q2Q % growth | -0.27 | -0.50 | 0.23 | 46.52% |
| Q3 2021 Q2Q % growth | -0.12 | -0.18 | 0.06 | 34.64% |
| Q2 2021 Q2Q % growth | -0.12 | -0.18 | 0.06 | 33.16% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2022 Q2Q % growth | 110.497K | -110.497K | -100.00% | |
| Q3 2022 Q2Q % growth | 132.6K | -132.6K | -100.00% | |
| Q2 2022 Q2Q % growth | -100.00% | 132.6K | -132.6K | -100.00% |
| Q1 2022 Q2Q % growth | -100.00% | 331.5K | -331.5K | -100.00% |
| Q4 2021 Q2Q % growth | -100.00% | 165.75K | -165.75K | -100.00% |
| Q3 2021 Q2Q % growth | -100.00% | 293.25K | -293.25K | -100.00% |
| Q2 2021 Q2Q % growth | 1.96M 3,166.67% | 499.8K | 1.46M | 292.16% |
| Q1 2021 Q2Q % growth | 760K 850.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 10.56% | -0.84% | -1.79% | -1.79% |
| Revenue | N/A | N/A | N/A | N/A |